Arvinas (NASDAQ:ARVN) Reaches New 12-Month Low – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN)’s stock price hit a new 52-week low during trading on Thursday . The stock traded as low as $7.83 and last traded at $7.85, with a volume of 677217 shares changing hands. The stock had previously closed at $7.95.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ARVN shares. Oppenheimer lowered shares of Arvinas from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $81.00 price target on shares of Arvinas in a research note on Tuesday, March 11th. Bank of America dropped their price objective on Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. BTIG Research initiated coverage on Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. Finally, Wedbush cut shares of Arvinas from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $57.00 to $12.00 in a report on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Arvinas presently has an average rating of “Moderate Buy” and a consensus target price of $35.50.

Arvinas Trading Up 0.5 %

The company’s 50-day simple moving average is $15.67 and its 200-day simple moving average is $20.91. The stock has a market capitalization of $549.49 million, a price-to-earnings ratio of -2.87 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the business earned ($2.53) earnings per share. On average, equities research analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last ninety days. 5.23% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arvinas

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in Arvinas in the fourth quarter valued at approximately $28,000. KBC Group NV increased its stake in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the period. KLP Kapitalforvaltning AS bought a new position in Arvinas during the fourth quarter worth $171,000. Finally, Tema Etfs LLC acquired a new stake in Arvinas in the fourth quarter worth $227,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.